Integra LifeSciences (NASDAQ:IART) Posts Earnings Results, Beats Expectations By $0.12 EPS

Integra LifeSciences (NASDAQ:IART - Get Free Report) announced its quarterly earnings results on Tuesday. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.85 by $0.12, Zacks reports. The firm had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences's quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.89 earnings per share.

Integra LifeSciences Stock Up 0.7 %

IART stock traded up $0.15 during trading on Friday, reaching $23.21. 698,610 shares of the company traded hands, compared to its average volume of 618,446. The business has a 50 day simple moving average of $23.77 and a 200 day simple moving average of $21.85. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $40.92. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -257.86, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Morgan Stanley started coverage on Integra LifeSciences in a report on Monday, December 2nd. They issued an "underweight" rating and a $20.00 target price for the company. Citigroup upped their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $23.00.

Insiders Place Their Bets

In other news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares of the company's stock, valued at $1,357,357.12. The trade was a 2.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.10% of the stock is currently owned by corporate insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.